What if you could design something that acts like an antibody, but cheaper, more stable, and made entirely with chemistry?
Two LACDR researchers, Sebastian Pomplun and Matthias Barz, teamed up to do just that. By merging peptide synthesis with polymer chemistry, they developed synthetic molecules that mimic the size, shape, and function of antibodies, without the cold storage, high production costs, or immune side effects.
These ‘bottlebrush-like’ nanoscale particles are tough, modular, and ready for next-gen therapies. The concept worked from the very first experiment. The potential? Faster drug development, better patient access, and new pathways for targeting disease.
Read the full story here.
MIMETAS, a leading organ-on-a-chip company, has announced the publication of a new peer-reviewed study that marks a major advance in cardiovascular disease research. The study,...
NecstGen has partnered with Paris-based biotech Astraveus to evaluate the Lakhesys™ Benchtop Cell Factory™, a microfluidic-based platform aiming to simplify and scale CAR-T...
Leiden Bio Science Park welcomed a high-level Shanghai delegation, led by Vice Mayor Liu Duo, marking a key step toward international collaboration in life sciences. The visit, initiated by Shanghai, showcased mutual interest in innovation and partnership.